Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort

Optimal treatment of breast cancer is increasingly dependent on genomic profiling, with several recent approvals of therapies targeting specific genomic alterations. This study examined the landscape of alterations with strong clinical significance, as per AMP-ASCO-CAP recommendations, detected by comprehensive genomic profiling in a cohort of 987 breast cancer patients tested as a part of routine clinical care. Our analysis identified one or more clinically significant genomic alterations (Tier IA) in 37.5% (370/987) of patients with breast cancer, which emphasizes the value of comprehensive genomic profiling to inform therapeutic decision-making.